Skip to main content

ASCPT 2025 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

E
PII-118
EFAVIRENZ ALTERS THE DISPOSITION AND PHARMACODYNAMICS OF TIZANIDINE IN HEALTHY VOLUNTEERS

Favorite
PI-065
EFFECT OF FOOD AND ESOMEPRAZOLE ON THE PHARMACOKINETICS (PK) OF BAY 2927088

Favorite
PI-029
EFFECT OF HEPATIC FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ

Favorite
PI-127
EFFECT OF HYPERTENSION (HTN) AND BLOOD PRESSURE (BP) CONTROL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.

Favorite
PI-105
EFFECT OF INDUCED HYPOGLYCEMIA ON OXIDATIVE STRESS IN HEALTHY VOLUNTEERS AND THE POTENTIAL APPLICATIONS OF N-ACETYLCYSTEINE

Favorite
PII-105
EFFECT OF P-GLYCOPROTEIN INHIBITION ON TWO TACROLIMUS FORMULATIONS: A RANDOMIZED, 4-SEQUENCE, CROSS-OVER, DRUG-DRUG INTERACTION STUDY

Favorite
PII-029
EFFECT OF RENAL FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ

Favorite
PI-030
EFFECT OF VALEMETOSTAT ON THE PHARMACOKINETICS OF MIDAZOLAM AND DIGOXIN (CYP3A AND P-GP SUBSTRATES): A PHASE 1 DRUG-DRUG INTERACTION STUDY IN PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA.

Favorite
PII-017
EFFECTS OF HIV AND OPIOIDS ON CHEMOKINE EXPRESSION IN AN INFECTIOUS MOUSE MODEL

Favorite
PII-111
ESTABLISHING EVIDENCE-BASED, ANTENATAL DOSE RECOMMENDATIONS FOR AMOXICILLIN (WITH AND WITHOUT CLAVULANIC ACID)

Favorite
PI-112
ESTIMATION OF THE AREA UNDER THE CURVE OF MYCOPHENOLIC ACID CONCENTRATION IN CHINESE PEDIATRIC RENAL TRANSPLANT PATIENTS USING LIMITED SAMPLING METHOD.

Favorite
PI-119
EUGLYCEMIC CLAMP STUDY DESIGNS FOR NOVEL INSULINS AND INSULIN BIOSIMILARS.

Favorite
PII-119
EVALUATING AND OPTIMIZING ALLOMETRIC SCALING APPROACHES FOR PREDICTING PEDIATRIC EXPOSURES OF INTRAVENOUSLY ADMINISTERED SMALL MOLECULES AND BIOLOGICS FROM ADULT DATA

Favorite
PII-013
EVALUATING DRUG-DRUG INTERACTIONS WITH ACID-REDUCDING AGENTS: INSIGHTS FROM FDA GUIDANCE AND RECENT APPROVALS

Favorite
PII-004
EVALUATING THE UTILITY OF ENDOGENOUS OCT2 AND MATE1/2-K BIOMARKERS FOR EARLY DDI ASSESSMENT IN ONCOLOGY PHASE 1 STUDIES

Favorite
TIP-002
EVALUATION OF A PHARMACIST-LED PHARMACOGENETICS CONSULTATION SERVICE ON HEALTHCARE COSTS AND OUTCOMES.

Favorite
PII-009
EVALUATION OF ANTIBIOTIC TREATMENTS FOR CELLULITIS: A SYSTEMATIC REVIEW FROM CLINICALTRIALS.GOV

Favorite
OAI-002
EVALUATION OF CAUSAL INFERENCE OF BILE ACIDS ON CARFILZOMIB RELATED CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA BY MENDELIAN RANDOMIZATION

Favorite
PT-007
EVALUATION OF CAUSAL INFERENCE OF BILE ACIDS ON CARFILZOMIB RELATED CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA BY MENDELIAN RANDOMIZATION

Favorite
PT-024
EVALUATION OF PRESCRIBER BEHAVIOR IN RESPONSE TO CYP2C19-CLOPIDOGREL BEST PRACTICE ALERTS.

Favorite
PT-025
EVALUATION OF PYRAZINAMIDE PHARMACOKINETICS IN ADOLESCENTS AND ADULTS TO INFORM TUBERCULOSIS DOSING RECOMMENDATIONS.

Favorite
LB-012
EVALUATION OF THE EFFECT OF CYP3A4 AND P-GLYCOPROTEIN INHIBITION BY ITRACONAZOLE OR INDUCTION BY RIFAMPICIN ON THE PHARMACOKINETICS OF ECOPIPAM AND ITS METABOLITES

Favorite
PI-066
EXPLORATORY POPULATION PHARMACOKINETICS AND WEIGHT LOSS MODELING OF HRS9531, A NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST IN CHINESE OBESE ADULTS

Favorite
LB-003
EXPLORING Δ-9-TETRAHYDROCANNABINOL (THC) INDUCED “FEELING HIGH” USING A PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC MODEL

Favorite
PT-026
EXPLORING THE RELATIONSHIP BETWEEN ANTIDEPRESSANT TREATMENT, NEUROCHEMICALS IN THE BRAIN AND ANXIETY/DEPRESSION SYMPTOMS IN YOUTH

Favorite
PII-067
EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE-2 TO HIGH-RISK MYELOFIBROSIS WITH OR WITHOUT PRIOR RUXOLITNIB EXPOSURE.

Favorite
PI-067
EXPOSURE-EFFICACY ANALYSIS OF CAMRELIZUMAB PLUS RIVOCERANIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA.

Favorite
PII-068
EXPOSURE-RESPONSE ANALYSES FOR EFFICACY AND SAFETY OF BMS-986365, A DUAL ANDROGEN RECEPTOR LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Favorite
PI-068
EXPOSURE-RESPONSE ANALYSIS OF MK-5475 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

Favorite
PII-069
EXTERNAL EVALUATION OF A POPULATION PHARMACOKINETICS MODEL OF CRITICALLY ILL PEDIATRIC PATIENTS RECEIVING MEROPENEM

Favorite
PT-003
EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA

Favorite
OAII-002
EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA

Favorite